MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), and Cidara Therapeutics, Inc. (“Cidara”), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. Read more.
